Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo.
about
Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute LeukemiaAdoptive T-cell therapy for LeukemiaRecognition and killing of cancer stem-like cell population in hepatocellular carcinoma cells by cytokine-induced killer cells via NKG2d-ligands recognitionIn Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid LeukemiaRe-evaluation of various molecular targets located on CD34+CD38-Lin- leukemia stem cells and other cell subsets in pediatric acute myeloid leukemia.5T4-specific chimeric antigen receptor modification promotes the immune efficacy of cytokine-induced killer cells against nasopharyngeal carcinoma stem cell-like cells.Adoptive cell transfer as personalized immunotherapy for human cancer.Chimeric antigen receptor T cell therapy in AML: How close are we?Chimeric antigen receptor-redirected CD45RA-negative T cells have potent antileukemia and pathogen memory response without graft-versus-host activityAnti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.Immunotherapy for hepatocellular carcinoma: From basic research to clinical use.Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia.Cytokine-induced killer (CIK) cells: from basic research to clinical translation.T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia.CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemiaTargeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platformCytokine-induced killer cells efficiently kill stem-like cancer cells of nasopharyngeal carcinoma via the NKG2D-ligands recognitionChimeric Antigen Receptor T Cell Therapy in Hematology.The novel structure make LDM effectively remove CD123+ AML stem cells in combination with interleukin 3.Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemiaInduction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy.CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.Sex chromosome loss and the pseudoautosomal region genes in hematological malignancies.Spontaneous remission of acute myeloid leukemia.Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies.Update on antigen-specific immunotherapy of acute myeloid leukemia.Emerging therapeutic targets in human acute myeloid leukemia (part 2) - bromodomain inhibition should be considered as a possible strategy for various patient subsets.New approaches for the immunotherapy of acute myeloid leukemia.Cytokine-induced killer cells as immunotherapy for solid tumors: current evidence and perspectives.Therapeutic Targeting of Siglecs using Antibody- and Glycan-Based Approaches.CAR T-cell immunotherapy: The path from the by-road to the freeway?Recent developments in immunotherapy of acute myeloid leukemia.Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?Cancer Immunotherapy: Whence and Whither.CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cellsAnti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34(+) cells of juvenile myelomonocytic leukemia.Engineered T cells: the promise and challenges of cancer immunotherapy.
P2860
Q26781328-0DA87892-F3B9-4704-869E-8F7857062991Q27006934-DC76A99B-93E1-4D86-A000-D572A05C57B6Q27311035-958E6BB3-9B3D-4F69-BA00-81D27643F9AEQ28554677-E7359ECF-0A25-4806-A45D-05179136B1A5Q33429957-BE78EA96-1574-4678-99DE-FDB0249A333EQ33884816-A5F9857E-DC77-45F3-94FE-96ABEFAD7B4DQ34043643-09E618D0-9CB2-4B8F-9DD5-353EA7E2327CQ34545962-A1DC0671-8F8F-4C5E-8A68-B57135ED84E1Q34765959-EBDCC6DB-39E2-4F0D-9E03-F73815B2C8A2Q35146288-3B64F0EA-DF37-4A7A-AB38-0BC12FFA5ED8Q35546759-08A8BFB6-1FB3-479E-B1C3-81A30BE038EFQ35567765-1AFE9396-2957-436F-BE06-0D29430DAE91Q35591409-9ABEB4C8-FC06-4DB3-B987-3AEAF11BB9C1Q36121153-141BA4A1-7CFA-4A56-AB41-21ABA4F55974Q36219592-9F163FC7-96D7-4CD6-8C39-DCB99F918157Q36279306-BAECE6C2-E35A-4407-86DE-117A17E5D1FAQ36443107-AB24089E-DE18-4FB3-9939-EF7D69C51903Q36544290-9E94F7E2-34B6-46CF-8A90-B479C25C86C8Q36722700-069867A6-B675-4DB5-BD18-30D3D8AB96B1Q36838862-FDE2634A-0CE2-4BEF-A8C1-6A043BCEA8D9Q36946572-82319F78-B2F4-405F-A226-EB6FFA1538AEQ37022306-C733164F-FED2-4CAC-80B2-07E9AD42211BQ37587956-0A38FE23-BF00-4505-ABB3-5E988B3D94F9Q37588329-A4B4C56F-443E-423E-9151-5CA70FF278F9Q37687827-5164E124-7321-48C3-9FED-6AB3D1F673DAQ38256921-A106CBE3-D49D-4422-9E23-95CDECFF1533Q38289029-FB91486F-1A28-4943-ADED-AB9DA0BB4C2EQ38432103-41896E88-A751-4E92-8461-A16CE9DDB293Q38435352-895AABF3-6CE4-4647-AF91-C3D767389DD1Q38482206-88F77848-9A13-4FFB-9AE5-3344730004E8Q38574526-8B3049AF-FC08-49F6-9CBA-97F017038BA0Q38598881-12731AB2-7EE6-4E4F-A8DB-CE5F56F851C4Q38632105-8D4FB590-9743-4D4D-A898-4AB2E401B23EQ38661895-AB2E5BD0-9035-4137-A6D3-422A7C79AC47Q38700209-D1E7D45C-34B7-4DC8-93C5-EEF310042D57Q38737924-DE0289CE-BF0A-4402-BA0A-9EB150171483Q38758807-0D76418D-A257-4248-B64C-1871BDADBC1BQ38766349-56FACA9D-E2F2-44D2-9720-83791AEB9EA4Q38785870-ED79535B-9D7E-42B8-9282-83344F8ABDF8Q38828829-B84E3103-FC45-44ED-8B1A-DD0C6AE97224
P2860
Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Chimeric antigen receptors aga ...... yeloid leukemia cells in vivo.
@en
Chimeric antigen receptors aga ...... yeloid leukemia cells in vivo.
@nl
type
label
Chimeric antigen receptors aga ...... yeloid leukemia cells in vivo.
@en
Chimeric antigen receptors aga ...... yeloid leukemia cells in vivo.
@nl
prefLabel
Chimeric antigen receptors aga ...... yeloid leukemia cells in vivo.
@en
Chimeric antigen receptors aga ...... yeloid leukemia cells in vivo.
@nl
P2093
P2860
P356
P1433
P1476
Chimeric antigen receptors aga ...... myeloid leukemia cells in vivo
@en
P2093
F Anjos-Afonso
F Lassailly
I Pizzitola
O Spinelli
P2860
P2888
P304
P356
10.1038/LEU.2014.62
P577
2014-02-07T00:00:00Z